{'fraction_non_alphanumeric': 0.04120443740095087, 'fraction_numerical': 0.02377179080824089, 'mean_word_length': 6.181818181818182, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparison of technetium‐99m sestamibi and indium‐111 octreotide imaging in a patient with ewing's sarcoma before and after stem cell transplantation

We report the use of two novel nuclide agents, Technetium‐99m (99Tc)sestamibi (MIBI) and indium‐111 (In‐111) octreotide, in comparison with conventional computed tomography (CT) imaging in a patient with metastatic Ewing's sarcoma (ES) before and after high dose chemotherapy with autologous peripheral stem cell transplantation (PSCT). MIBI is taken up actively by metabolically active tumor cells. Octreotide, a somatostatin analog, binds specifically to somatostatin receptors.